Integrare research unit (UMR_S951), Université Paris-Saclay université d’Evry, Inserm, Genethon Evry; ART-TG (Inserm US35), Corbeil-Essonnes
Anne Galy was trained in immunology and hematology and has more than 20 years of experience in cell and gene therapy. Currently, she heads the academic research unit of Genethon, dedicated to gene therapy of rare diseases (www.genethon.fr). She also heads the newly-established “technological research accelerator in genomic therapy” (ART-TG), an Inserm innovation and development center for cell and gene therapy (www.art-tg.com).
Anne Galy’s research interests revolve around immunology and technologies for gene therapy. At Genethon she has studied immune responses to viral vectors. She has also developed clinical gene therapies to treat primary immune disorders in collaboration with a broad network of international centers. She has recently established the ART-TG industrial integrator to develop new ex vivo gene therapy products particularly for immunotherapy to treat cancer or infectious diseases.
Author of more than 120 peer-reviewed articles, Dr. Galy’s activities are funded by several active grants including european commission funding. Dr. Galy was a contributor to the 3rd national plan for rare diseases in France and is currently a member of the scientific counsel of the Faculty of Medicine of the Université Paris-Saclay, a member of the scientific counsel of the IBISA platforms and a member of the Vaccine Research Institute. Dr. Galy is also a member of the International committee of ASGCT. She was formely on the board of the French Society of Cell and Gene Therapy.